Galinpepimut-S + Azacitidine + Venetoclax + Decitabine + Cytarabine + GM-CSF
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Feb 8, 2021 → Dec 1, 2026
NCT ID
NCT04229979About Galinpepimut-S + Azacitidine + Venetoclax + Decitabine + Cytarabine + GM-CSF
Galinpepimut-S + Azacitidine + Venetoclax + Decitabine + Cytarabine + GM-CSF is a phase 3 stage product being developed by SELLAS Life Sciences for Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT04229979. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04229979 | Phase 3 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia